drugset / Trial / NCT00755846
Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the safety and efficacy of alogliptin, once daily (QD), compared to diet and exercise, sulfonylurea, metformin and a combination of sulfonylurea and metformin for treating subjects with type 2 diabetes.
Timeline
- Start
- 2005-03
- Primary completion
- 2005-10
- Completion
- 2005-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alogliptin | Unknown | 6.25 mg | Oral |
| Subject | Alogliptin | Unknown | 12.5 mg | Oral |
| Subject | Alogliptin | Unknown | 25 mg | Oral |
| Subject | Alogliptin | Unknown | 50 mg | Oral |
| Subject | Alogliptin | Unknown | 100 mg | Oral |